RetinaCME

This activity is expired and is no longer available for CME credit.

VIDEOCMEABO MOC

Examining the Impact of Early Treatment and Injection Protocol Selection on Outcomes in Diabetic Retinopathy

Author(s)/Faculty: John W. Kitchens, MD; W. Lloyd Clark, MD
Release Date: 12/31/2020Expiration Date: 12/30/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: VideoProvider:
The utilization of intravitreal anti-vascular endothelial growth factor (VEGF) therapies as early intervention in diabetic retinopathy (DR) has provided reduced vision-threatening complications and significant slowing of disease progression for these patients. With the potential to delay disease progression and enhance quality-of-life measures in patients with DR, optimal integration of anti-VEGF therapies into current treatment protocols is imperative. Within this CME activity, experts in the field review the latest clinical data assessing the efficacy of anti-VEGF therapy in DR, as well as evaluate current therapeutic regimens for their ability to achieve regression of DR.